2617 — TransThera Sciences (Nanjing) Balance Sheet
0.000.00%
- HK$11.01bn
- HK$11.02bn
Annual balance sheet for TransThera Sciences (Nanjing), fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
---|---|---|
Period Length: | — | — |
Source: | PROSPECTUS | PROSPECTUS |
Standards: | IFRS | IFRS |
Status: | Final | Final |
Cash | ||
Short Term Investments | ||
Cash and Short Term Investments | 838 | 573 |
Net Total Receivables | 0.602 | 0.456 |
Total Inventory | ||
Prepaid Expenses | ||
Total Other Current Assets | ||
Total Current Assets | 846 | 585 |
Gross Property, Plant And Equipment | ||
Accumulated Depreciation | ||
Net Property, Plant And Equipment | 31.6 | 28.8 |
Net Intangible Assets | ||
Long Term Notes Receivable | ||
Other Long Term Assets | ||
Total Assets | 887 | 630 |
Accounts Payable | ||
Accrued Expenses | ||
Notes Payable / Short Term Debt | ||
Current Portion of Long Term Debt / Capital Leases | ||
Total Other Current Liabilities | ||
Total Current Liabilities | 103 | 103 |
Capital Lease Obligations | ||
Total Long Term Debt | ||
Total Debt | ||
Total Liabilities | 104 | 105 |
Common Stock | ||
Additional Paid In Capital | ||
Retained Earnings (Accumulated Deficit) | ||
ESOP Debt Guarantee | ||
Other Equity | ||
Total Equity | 783 | 525 |
Total Liabilities & Shareholders' Equity | 887 | 630 |
Total Common Shares Outstanding |